摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,4-Dihydro-2-[[(4-methoxyphenyl)methyl]-thio]-6-methyl-4-(3-nitrophenyl)-5-pyrimidinecarboxylic acid, 1-methylethyl ester, monohydrochloride | 108932-01-0

中文名称
——
中文别名
——
英文名称
1,4-Dihydro-2-[[(4-methoxyphenyl)methyl]-thio]-6-methyl-4-(3-nitrophenyl)-5-pyrimidinecarboxylic acid, 1-methylethyl ester, monohydrochloride
英文别名
(+)-1,4-Dihydro-2-[[(4-methoxyphenyl)methyl]thio]-6-methyl-4-(3-nitrophenyl)-5-pyrimidinecarboxylic acid, 1-methylethyl ester hydrochloride;propan-2-yl 2-[(4-methoxyphenyl)methylsulfanyl]-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyrimidine-5-carboxylate;hydrochloride
1,4-Dihydro-2-[[(4-methoxyphenyl)methyl]-thio]-6-methyl-4-(3-nitrophenyl)-5-pyrimidinecarboxylic acid, 1-methylethyl ester, monohydrochloride化学式
CAS
108932-01-0
化学式
C23H25N3O5S*ClH
mdl
——
分子量
491.996
InChiKey
XXWRFAAOGHSZDW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.18
  • 重原子数:
    33
  • 可旋转键数:
    8
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    131
  • 氢给体数:
    2
  • 氢受体数:
    7

反应信息

  • 作为产物:
    描述:
    6-methyl-5-(isopropyloxyarbonyl)-4-(3-nitrophenyl)-3,4-dihydropyrimidin-2(1H)-thione4-甲氧基氯苄乙醚 作用下, 以 四氢呋喃乙醚 为溶剂, 反应 25.0h, 以to afford (+)-1,4-dihydro-2-[[(4-methoxyphenyl)methyl]thio]-6-methyl-4-(3-nitrophenyl)-5-pyrimidinecarboxylic acid, 1-methylethyl ester hydrochloride, 493 mg (38%)的产率得到1,4-Dihydro-2-[[(4-methoxyphenyl)methyl]-thio]-6-methyl-4-(3-nitrophenyl)-5-pyrimidinecarboxylic acid, 1-methylethyl ester, monohydrochloride
    参考文献:
    名称:
    1,2,3,4-Tetrahydro-6-substituted-4-aryl(or heterocyclo)-3-((substituted
    摘要:
    具有以下式子及其药学可接受的盐的化合物表现出心血管活性,其中X为氧或硫;R为氢,烷基,环烷基,芳基或芳基烷基,R1为氢,烷基,环烷基,芳基,杂环烷基,或卤代烷基,或R和R1与它们所连接的氮原子一起取1-吡咯烷基,1-哌啶基,1-氮杂七环基,4-吗啉基,4-噻吗啉基,1-哌嗪基,4-烷基-1-哌嗪基,4-芳基烷基-1-哌嗪基,4-二芳基烷基-1-哌嗪基或1-吡咯烷基,1-哌啶基或1-氮杂七环基,用烷基,烷氧基,烷硫基,卤素,三氟甲基或羟基取代;R2为氢,烷基,烯基,炔基,环烷基,芳基,或卤代烷基;R3为氢,烷基,环烷基,芳基,杂环烷基,或卤代烷基;R4为芳基或杂环烷基;R5和R6各自独立地为氢,烷基,-(CH2)q-芳基或-(CH2)q-环烷基;Y1为环烷基,芳基,杂环烷基,羟基,烷氧基,芳基-(CH2)m-O-,巯基,烷硫基,芳基-(CH2)m-S-,氨基,取代氨基,氨基甲酰基,-NH-CO-,或-CH2-CH2-NH-CO-;Y3为羟基,烷氧基,芳基-(CH2)m-O-,巯基,烷硫基,芳基-(CH2)m-S-,-NH-CO-,取代氨基或氨基;q为0,1,2或3;m为0或1到6的整数;n为0或1到5的整数;p为1到5的整数。
    公开号:
    US04855301A1
点击查看最新优质反应信息

文献信息

  • 2-thio or oxo-4-aryl or heterocyclo-1,5(2H)-pyrimidinedicarboxylic acid
    申请人:E. R. Squibb & Sons, Inc.
    公开号:US05202330A1
    公开(公告)日:1993-04-13
    Pyrimidine compounds of the formula ##STR1## wherein X is sulfur or oxygen, Y is R.sub.11 or --O--R.sub.1, and R.sub.4 is aryl or heterocyclo are disclosed. These compounds are useful as cardiovascular agents, particularly anti-hypertensive agents, due to their calcium entry blocking vasodilator activity.
    公开了符合以下公式的嘧啶化合物##STR1##其中X是硫或氧,Y是R.sub.11或--O--R.sub.1,R.sub.4是芳香族或杂环。这些化合物由于其钙通道阻滞血管扩张剂活性而被用作心血管药物,特别是抗高血压药物。
  • 1,2,3,4-Tetrahydro-6-substituted-4-aryl(or heterocyclo)-3-((substituted
    申请人:E. R. Squibb & Sons, Inc.
    公开号:US04855301A1
    公开(公告)日:1989-08-08
    Cardiovascular activity is exhibited by compounds having the formula ##STR1## and pharmaceutically acceptable salts thereof wherein X is oxygen or sulfur; R is hydrogen, alkyl, cycloalkyl, aryl, or arylalkyl and R.sub.1 is hydrogen, alkyl, cycloalkyl, aryl, heterocyclo, ##STR2## or halo substituted alkyl, or R and R.sub.1 taken together with the nitrogen atom to which they are attached are 1-pyrrolidinyl, 1-piperidinyl, 1-azepinyl, 4-morpholinyl, 4-thiamorpholinyl, 1-piperazinyl, 4-alkyl-1-piperazinyl, 4-arylalkyl-1-piperazinyl, 4-diarylalkyl-1-piperazinyl or 1-pyrrolidinyl, 1-piperidinyl, or 1-azeipinyl substituted with alkyl, alkoxy, alkylthio, halo, trifluoromethyl or hydroxy; R.sub.2 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, ##STR3## or halo substituted alkyl; R.sub.3 is hydrogen, alkyl, cycloalkyl, aryl, heterocyclo, ##STR4## or halo substituted alkyl; R.sub.4 is aryl or heterocyclo; R.sub.5 and R.sub.6 are each independently hydrogen, alkyl, --(CH.sub.2).sub.q --aryl or --(CH.sub.2).sub.q --cycloalkyl; Y.sub.1 is cycloalkyl, aryl, heterocyclo, hydroxyl, alkoxy, aryl--(CH.sub.2).sub.m --O--, mercapto, alkylthio, aryl--(CH.sub.2).sub.m --S--, amino, substituted amino, carbamoyl, ##STR5## Y.sub.3 is hydroxyl, alkoxy, aryl--(CH.sub.2).sub.m --O--, mercapto, alkylthio, aryl--(CH.sub.2).sub.m --S--, ##STR6## amino, or substituted amino; q is 0, 1, 2 or 3; m is 0 or an integer of 1 to 6; n is 0 or an integer of 1 to 5; and p is an integer of 1 to 5.
    具有以下式子及其药学可接受的盐的化合物表现出心血管活性,其中X为氧或硫;R为氢,烷基,环烷基,芳基或芳基烷基,R1为氢,烷基,环烷基,芳基,杂环烷基,或卤代烷基,或R和R1与它们所连接的氮原子一起取1-吡咯烷基,1-哌啶基,1-氮杂七环基,4-吗啉基,4-噻吗啉基,1-哌嗪基,4-烷基-1-哌嗪基,4-芳基烷基-1-哌嗪基,4-二芳基烷基-1-哌嗪基或1-吡咯烷基,1-哌啶基或1-氮杂七环基,用烷基,烷氧基,烷硫基,卤素,三氟甲基或羟基取代;R2为氢,烷基,烯基,炔基,环烷基,芳基,或卤代烷基;R3为氢,烷基,环烷基,芳基,杂环烷基,或卤代烷基;R4为芳基或杂环烷基;R5和R6各自独立地为氢,烷基,-(CH2)q-芳基或-(CH2)q-环烷基;Y1为环烷基,芳基,杂环烷基,羟基,烷氧基,芳基-(CH2)m-O-,巯基,烷硫基,芳基-(CH2)m-S-,氨基,取代氨基,氨基甲酰基,-NH-CO-,或-CH2-CH2-NH-CO-;Y3为羟基,烷氧基,芳基-(CH2)m-O-,巯基,烷硫基,芳基-(CH2)m-S-,-NH-CO-,取代氨基或氨基;q为0,1,2或3;m为0或1到6的整数;n为0或1到5的整数;p为1到5的整数。
查看更多